ROIV
ROIV
Company information not available. Track real-time insider trading activity, SEC Form 4 filings, and executive stock transactions.
Insider Buys
0
$0
Insider Sales
7
$194.69M
Total Volume
$194.69M
68 transactions
Net Activity
$194.69M
Net selling
Sentiment Rating
Heavy DistributionCEO Conviction Index
Liquidating / Profit Taking
Key Drivers
- •Heavy distribution: sales represent 100% of total transaction value.
- •CEO selling activity detected. Often driven by option expiration or diversification plans.
- •Significant liquidation: total sale value exceeds $10M.
Score Methodology
The Insider Confidence Score (1-100) measures executive conviction. Starting from a neutral 50, it adjusts based on:
- +15Strong Buy Ratio: Purchases > 70% of volume (or up to -15 for heavy sales).
- +20Cluster Buying: ≥3 unique insiders buying within a 30-day window.
- +15CEO Buying: CEO committing own capital shows high conviction.
- +10CFO Buying: CFO purchasing shares shows financial alignment.
Multiple Insiders
S - Sale Insiders
$57.31B total
Qvt Financial LP
Director by Deputization
$53.54M total
Manchester Keith S
Dir
$53.54M total
Gold Daniel Allen
Dir
$53.54M total
Venker Eric
Pres, Immunovant CEO
$21.60M total
Quick Actions
ROIV has an insider buy conviction of 0%, compared to the Unknown sector buy average of 6%. ROIV ranks #10 in insider activity out of 569 tracked companies in its industry.
Over the last 90 days, corporate insiders at ROIV (ROIV) engaged in a total of 68 transactions reported via SEC Form 4 filings. Among these, 0 were open-market purchases and 7 were sales. The total volume of insider trading reached $194.69M.
The net insider activity for ROIV shows a net selling bias of $194.69M. This activity represents a 0% buy ratio, suggesting that insiders are currently bearish on the company's near-term outlook relative to recent history.
The most notable individual transaction was a Sale by Multiple Insiders (P - Purchase Insiders), who traded 17.29M shares valued at $57.31B on Sep 18, 2025.
Roivant Sciences Ltd. (ROIV) Stock Price, News, Quote & History
Keith Manchester Sells $54M Of Roivant Sciences Stock After Sharp Run-Up
In his first ownership report, Roivant Sciences (ROIV) director Jeffrey Evan Hammerbacher lists no holdings.
Roivant Sciences Ltd. (ROIV) Stock Forecasts
Roivant Sciences Insider Sold Shares Worth $53,536,738, According to a Recent SEC Filing
ROIV Stock Jumps As LISRAYA FDA Approval Ignites Momentum
FAQs About ROIV Insider Trading
Answers to common questions regarding corporate filings and executive sentiment for ROIV.